Month: March 2022

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021 BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part Phase 1b/2a trial of GB1211, GULLIVER-2, in liver cirrhosis. GB1211 is a selective, oral small molecule inhibitor of galectin-3 being studied in liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and for which there are limited treatment options. GULLIVER-2 is an innovative hybrid trial, combining a hepatic impairment trial of safety, tolerability and pharmacokinetics...

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the completion of patient enrollment in the ASSERT study, a Phase 3 pivotal trial of Bylvay (odevixibat) in patients with Alagille syndrome (ALGS). Topline results are expected to be available by the end of the year, consistent with guidance, and with the enrollment of 52 patients versus an original target of 45. ASSERT is a gold standard, global, double-blind, randomized, placebo-controlled trial designed to evaluate the safety and efficacy of Bylvay in patients with ALGS over 24 weeks. Both the U.S. FDA and EMA have...

Vancouver, BC, March 29, 2022 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt), is pleased to announce that the 2022 exploration program has been completed at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, Canada. Drilling for the 2022 winter season at the East Preston Project commenced in late January and a total of 5,004 metres were completed in 19 drill holes, which was cut slightly short due to the onset of warm weather. Drilling was focused on the G-, K-, and H-Zones with prior progress reported in news releases dated February 14th, 2022, March 1st, 2022, and March 16th, 2022. Packing up and demobilizing of the drill equipment and camp is underway with decommissioning of the road expected...

SFLMaven Scores Another Strong Week of Sales with Nearly $285k for the Seven Days Ended March 24 Heavy Platinum 6.25CTW VS1/F diamond cluster floral ribbon brooch. Sold for $4,739 at last week’s SFLMaven Famous Thursday Night AuctionSFLMaven Scores Another Strong Week of Sales with Nearly $285k for the Seven Days Ended March 24 Heavy 14k yellow gold 10.29ct diamond line tennis bracelet. Sold for $5,600FORT LAUDERDALE, FL, March 29, 2022 (GLOBE NEWSWIRE) — SFLMaven Corp. (OTC Pink: SFLM), (“SFLMaven” or the “Company”) (www.sflmaven.com), a leading provider of high-end luxury goods, is excited to announce unaudited performance results for the week ended Thursday, March 24, 2022.Total Sales of $283k for seven days ended Mar 24 Mar 24 Thursday Night Auction Sales of more than 258k March 2022 on pace...

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.25 per share and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of its common stock at a public offering price of $0.24 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. Each share of common stock or pre-funded warrant is being sold together with one, immediately exercisable common warrant with a five year term to purchase...

SharpLink’s Data-Driven Customer Acquisition Model Showing Increased Results in All Key Conversion Metrics MINNEAPOLIS, March 29, 2022 (GLOBE NEWSWIRE) — SharpLink Gaming Ltd. (Nasdaq:SBET) (“SharpLink” or the “Company”), a pioneer of targeted, data-driven user engagement and conversion solutions for the emerging U.S. sports betting and iGaming industries, today reported that the Company’s integrated C4 solution resulted in a measurable improvement in the conversion of NASCAR.com fans to sports betting depositors with BetMGM for the first five weeks of the 2022 NASCAR racing season. Currently, SharpLink is featuring a BetMGM bet slip module on NASCAR.com’s home page that incorporates C4 bet recommendation algorithms in states where online sports betting has been legalized. Once a NASCAR fan clicks on the bet slip, a BetMGM promotional...

– Further progress made against previously announced balance sheet strengthening and strategic initiatives IRVING, Texas, March 29, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA), announced today that certain of its subsidiaries closed a Revolving Loan Exchange and Prepayment Agreement with the financial institutions acting as revolving lenders under its First Lien Credit Agreement dated as of July 12, 2017. All of the amounts outstanding under the revolving facility were prepaid with $50 million of cash and the remainder exchanged for $50 million of 11.500% First-Priority Senior Secured Notes due 2026. As a result, there are no further senior debt maturities in 2022. The closing of the revolver is one of the last steps in the initiative to strengthen the balance sheet announced...

The Company is working toward multiple deals to drive shareholder value by adding IP, talent and operating assets LOS ANGELES, March 29, 2022 (GLOBE NEWSWIRE) — via InvestorWire – ECGI HOLDINGS INC. (OTC: ECGI) (“ECGI” or the “Company”), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, is pleased to offer current and prospective shareholders with the following update on the Company’s operations. “We are working to finalize a transaction to acquire key assets that will serve the purpose of granting us our Major Use License for the upcoming year so we can start our cultivation operations in full,” said William Chung, CEO of ECGI Holdings. Beyond that strategic move, management notes that the Company is working toward several key acquisitions...

LAKE OSWEGO, OR, March 29, 2022 (GLOBE NEWSWIRE) — PSYC Corporation (OTCPink: PSYC) (“PSYC” or the “Company”) a media leader for the emerging sector of medicinal psychedelics and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce the Company successfully secured $350,000 in equity-based financing. Pursuant to the terms of the investment, a total of 17,500,000 shares of PSYC common stock were sold at a price of $0.02 per share and include warrant options for the right to purchase up to an additional 20M shares over the next 12 months. The investment was completed by Trent Sullivan of Jackson, Tennessee and is a private, accredited investor.  “We are incredibly grateful to Mr. Sullivan for the resounding faith he is demonstrating in the future of PSYC by way of...

The Extraordinary General Meeting of shareholders of AB “Ignitis grupė” (hereinafter – the Group, legal entity code 301844044, registered office at Laisvės ave. 10, Vilnius, held on 29 March, 2022, adopted the following resolutions: 1.       Regarding the assent to AB “Ignitis grupė” consolidated annual report for the year 2021, except for the part of the remuneration report.1.1. To assent to AB „Ignitis grupė“ consolidated annual report for the year 2021, except for the part of the remuneration report (link). 2.       Regarding the assent to the remuneration report of AB “Ignitis grupė”, as a part of the consolidated annual report of AB “Ignitis grupė” for the year 2021.        2.1. To assent to the remuneration report of AB “Ignitis grupė”, as a part of the consolidated annual report of AB “Ignitis grupė” for the year 2021 (link). 3.      ...